GlassScriptPhysician profile
Manuel V Ramos
NPI 1427166222
$15,042.75
in general payments reported to CMS, 2019-2025
55 companies · $2,433 in 2025
The $2,433 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $1,416 · 2021: $2,920 · 2022: $3,807 · 2023: $1,622 · 2024: $1,780 · 2025: $2,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,736 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,735.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,827.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,657.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,570.52 | 2021-2025 | |
| Lilly USA, LLC | $1,100.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biotissue Holdings INC. | $872.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $796.56 | 2020-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $703.17 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $571.10 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Optinose US, INC. | $475.36 | 2019-2025 | |
| Pfizer INC. | $466.93 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $423.63 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $369.53 | 2021-2025 | |
| Dexcom, INC. | $294.66 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $287.14 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Teva Pharmaceuticals USA, INC. | $282.96 | 2021-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.